Loading...
ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
PURPOSE: We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligible patients were randomly assigned to the GP (gemcitab...
Na minha lista:
| Udgivet i: | Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Korean Cancer Association
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5512356/ https://ncbi.nlm.nih.gov/pubmed/27737534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2016.365 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|